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Abstract
The current methods of publishing chemical information in bioscience articles are analysed. Using
3 papers as use-cases, it is shown that conventional methods using human procedures, including
cut-and-paste are time-consuming and introduce errors. The meaning of chemical terms and the
identity of compounds is often ambiguous. valuable experimental data such as spectra and
computational results are almost always omitted. We describe an Open XML architecture at
proof-of-concept which addresses these concerns. Compounds are identified through explicit
connection tables or links to persistent Open resources such as PubChem. It is argued that if
publishers adopt these tools and protocols, then the quality and quantity of chemical information
available to bioscientists will increase and the authors, publishers and readers will find the process
cost-effective.
Introduction
In a previous article [1] we have argued the value of
extracting the chemical information in bioscientific
research, transforming it to XML and redisseminating it
openly. The present article expands on the technical and
cultural infrastructure required to support this. The tech-
nical aspects have been solved to proof-of-concept stage
and we are starting to embark on experiments in the social
domain. In this we thank BMC for inviting us to submit
this and we present a model here which we believe could
be attractive for bioscience publishers and their
community.
We concentrate on the current publication of chemistry in
bioscience. This includes:
1. mention of chemical compounds.
2. details of synthesis (in vivo and in vitro) of
compounds.
3. proof of structure (spectra and analytical data).
4. Methods and reagents in bioscience bio-protocols
5. properties of compounds.
6. reactions and their properties, both in enzymes and
enzyme-free systems.
This type of chemistry is very well understood and has a
simple ontology which has not changed over decades[2].
Unlike much bioscience, where ontological tools are an
essential part of reconciling the domain-dependent
approaches, much chemistry has an implicitly agreed
abstract description. The problems are primarily reconcil-
ing syntax and semantics. This is because chemists use
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abbreviated and lazy methods of communicating data,
relying on trained readers to add information from the
context. We have reviewed current problems of machine-
understanding of chemistry[3] in a typical chemistry jour-
nal, many of which are perpetuated by the graphical ori-
entation of conventional publishing houses. Here we take
the view that a committed publishing house can create a
cost-effective and human-tolerable system for authoring
semantically correct chemistry in (bio)scientific
documents.
We know from experience that Utopian visions do not sell
themselves. The enormous and accepted value of the
sequence and structures databases arose not from the
demands of individual authors, but from wider commu-
nities of researchers, funders, and learned societies. Even
now the deposition of protein structure data, without
which journals will not generally accept a paper, is seen by
some as a chore and at worst as the donation of informa-
tion to competitors. Without that commitment and the
resource, however, Structural Biology would not exist as a
discipline. Here we present the following vision; that
aggregated "small-molecule" chemical information, if
deposited at publication, aggregated and disseminated,
would be seen as worth paying the prices of
inconvenience.
Generic infrastructure
For this proposal we make some assumptions about the
evolving informatics environment:
• The costs of archiving and maintaining scientific infor-
mation can be now very much lower than some of the
more traditional approaches. There will always be areas
(patents, safety, reference data) where intensive human
effort is required in the curation of data and where com-
prehensiveness is critical. This argument will be strongly
made by the current chemical secondary publishers who
show no signs of changing their business model. However
bioscience has shown that informatics research is willing
to balance quantity and quality and accepts that data is
always used under caveat emptor.
• Much data is now completely captured instrumentally
and can, in principle, be transmitted without syntactic
loss. Crystallography has shown that experimental data
(in the CIF format) can be directly submitted to the pub-
lisher. Moreover with the development of expert pro-
grams it is possible to review the data by machine and that
this leads to higher quality than before. The global aggre-
gation of current small-molecule crystal structures, with-
out any secondary curators or publishers, can now meet
almost all the needs of the community.
• Most current publicly funded chemical data is never
published; loss varies between 80% (crystallography) and
99.9%. Much of this is due to the lack of simple technical
and cultural protocols, which we address later.
• The primary cost is human time. Storage and CPU costs
are trivial (for our domain). We show how the measures
here, if adopted, would save all members of the commu-
nity considerable time. They would also lead to the crea-
tion of greatly enhanced information resources.
• A variety of repositories will become available. In some
communities (e.g. Physics and Computer Science) self-
archiving of (p)reprints is universal but in others it is rare.
Early adopters of Institutional repositories (IRs) are start-
ing to mandate that the output of publicly funded schol-
arship is reposited, and we infer that, perhaps with
sharing schemes, this will become quasi-mandatory.
There is potential conflict with publishers' licenses, which
we address below.
• There will be sufficient publishers in bioscience who are
attracted by approaches like ours, and that this will create
a critical mass. The benefits will be interoperable
approaches to authoring (at present the technical require-
ments of some publishers are grotesque, i.e. hardcopy,
strange formats, etc.).
• Openness. Our approach does not require Open Access,
but does require that chemical data are Open.
• Willingness for bioscientists to take a lead in chemical
informatics. Chemical information sources are manually
aggregated and curated secondary publications whose
philosophy has barely altered over 120 years. There is a
large quasi-monopoly of a small number of large organi-
sations who have no interest or inclination in changing
their business models or adopting the vision of the
Semantic Web. These new technologies, however, are ide-
ally suited to our model and require only modest
investment.
• Open or cheap tools for publishing structured docu-
ments (in XML) which can be customised for different
domains. As XML becomes the universal technology for
publication and interoperability, the community has
access to them and will become trained in their use. As
Open source components become more widespread it
becomes possible to envisage scientific authoring tools
which meet many requirements of the publication
process.
We look to bioscience to take a lead in helping realise the
following vision. On the positive we now believe that
there are already enough Open tools and Open resourcesBMC Bioinformatics 2005, 6:180 http://www.biomedcentral.com/1471-2105/6/180
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which with communal will among bioscience authors and
publishers can make the vision attractive and cost-effec-
tive.
Automatic capture of chemical information
Much chemical data is largely context-free in that it can be
understood and recreated independently of the location
or motivation. The primary data model is over 120 years
old and was developed by Beilstein in the 19th century
and comprises three components: the chemical com-
pound, its properties and citations. A pure compound is
described by an immutable structural formula and has
precisely reproducible properties. There are qualifications
(e.g. some properties may depend on the precise crystal-
line form) but it has served as the basis of a multimillion
chemical information market, with the compound at the
centre. Current thinking asserts that the biological action
of a compound is, in principle, reproducible and predict-
able if the system is carefully enough replicated and the
components understood. This is the central dogma of the
chemically-based pharmaceutical industry.
Chemistry has a tradition of quality through properties
and analysis, so every new compound (and many resyn-
thesised ones) mentioned in the literature must be accom-
panied by measurements of properties to justify identity
and purity. These facts are available, in text form, in the
primary literature in which over a million new com-
pounds are published annually. Because structure predicts
properties, and because drug discovery is so difficult, the
pharmaceutical industry tests many compounds for bio-
logical activity. It is therefore the primary financial engine
for the chemical information industry.
The components
Techniques for managing items 1–5 listed above such as
aggregating chemical compounds, properties and for
searching the results, are very well understood and can be
easily made nearly automatic. Most of the information of
benefit to the community exists on the authors' comput-
ers in machine-processable form. It can be automatically
converted into fine-grained XML[4] with almost no loss.
The chemist has electronic copies of molecular structures,
spectra and properties whose semantics are extremely well
understood and where a simple technical protocol for
conversion to XML and hence publication can be created.
To support this part of the data publication process we
have created the XML-based Chemical Markup Language
(CML)[5]. The primary information components (all of
which are common and well understood) are:
• Molecular structure
A compound is described by a compositional formula
(e.g. CH3OH for methanol) and a graphical structural for-
mula ("2D diagram"). These descriptions are required in
bioscience publications for new compounds or where sci-
entific arguments are based on details of chemical struc-
ture. There are a few widely used standalone tools (mainly
commercial) for drawing structures and calculating cer-
tain properties. They output a variety of machine-process-
able formats (MDL Molfiles, ChemDraw CDX files, and
increasingly CML). The main challenge is that the output
is designed for the sighted human reader and that seman-
tics may be implicit, discussed below. The Open Source
community is creating tools (e.g. JChempaint[6]) that will
be valuable in authoring publications.
• Chemical entities and names
Many compounds have no explicit structures and are
mentioned by names or identifiers. Where these relate to
specific compounds (rather than generic such as "phe-
nols") it is valuable to link them to a precise
identification.
• Spectra
Many traditional formats (JCAMP and some manufactur-
ers) are satisfactorily machine-processable, and we expect
the XML-based AnIML[7] to be widely adopted by
manufacturers.
• Crystal Structures
Relatively few small-molecule crystal structures are
reported in bioscience publications, but when they are we
have a workflow-driven system that extracts the data auto-
matically and reposits it
• Molecular properties
These are required as proof-of-synthesis and use a small
dictionary of properties[8]. Their publication is highly rit-
ualised and we expect that a publisher-wide template for
the submission of this information would be straightfor-
ward to compile and welcomed by many authors.
Identifying compounds
The identification of chemical entities is the most valuable
contribution that an author can make. In most cases s/he
(as, say, the purchaser or creator of the materials) is the
best judge of what was used. It is more considerably more
difficult to identify compounds after publication as we
show below.
We list possible methods of publishing the identity of
compounds in machine-understandable form:
• Connection table
This is the most powerful method and we urge that every
report of a chemical synthesis be accompanied by a con-
nection table. It already exists in the authors' laboratory
(in MOL, Chemdraw, SMILES, and increasingly as CML).
It is rare that a pure molecule in the bioscience literatureBMC Bioinformatics 2005, 6:180 http://www.biomedcentral.com/1471-2105/6/180
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cannot be represented in this way. This is the single most
important recommendation in this manuscript.
• Chemical structure diagram
This is a useful adjunct to a connection table (and some of
the formats combine the two). Very occasionally (e.g. for
catenanes, helicenes) a diagram is essential, but it should
never be used instead of a connection table.
• InChI
For most compounds of bioscientific interest with known
structure it is possible to generate a unique identifier using
the new InChI (International Chemical Identifier)[9]
from IUPAC. This has major advantages over non-seman-
tic identifiers and Closed proprietary canonical identifiers
such as SMILES[10]. In principle an InChI not only
uniquely identifies the substance but also contains all the
essential structural information. InChI in its current ver-
sion (1.0) (and often other canonicalization schemes as
well) has some significant limitations for systems with
metal ions and ionic compounds, a situation which
apparently will be addressed in a future InChI revision.
Simple molecules such as e.g. cis-Platin are currently
included in the handling, although the stereochemical
aspects are not currently captured. Handling such aspects
of e.g. metal-based drugs must clearly be a high priority in
the development of InChI.
• Semantically free identifiers
These are provided by authorities (e.g. Chemical
Abstracts, RTECS, PubChem, etc.). To be useful they
should have an Open mechanism for their resolution (e.g.
in PubChem), but this is often expressly forbidden. Thus
Chemical Abstracts[11] forbids the public exposure of
more than 0.1% of its content. Unless persistent Open
machine-friendly resolution is available we deprecate the
use of authority-controlled identifiers as unique IDs in
primary publications. There are very few cases (e.g. zeo-
lites) where identifiers are the best means of
identification.
• Trivial ("Common") names
The structures of many compounds ("aspirin", "testoster-
one", "glycine"...) can only be found through lookup. In
the past these names have been controlled in Closed col-
lections but there are now an increasing number of Open
lexicons of names:structures. The NCI led the way
(220,000 names for ca 50,000 structures) and PubChem
[12] has continued to develop this. If commercial suppli-
ers make their catalogs Open then most of the common
chemical names in scientific discourse can be automati-
cally linked to connection tables.
• Systematic chemical names
Until now this has been a common means of transmitting
chemical identity, but it now serves little purpose,
although It may be required legally, e.g. for patents. Most
chemists would prefer a structural diagram to a systematic
name, and many regard name generation as a tedious
chore. In principle IUPAC[2] chemical names obey a con-
text-free grammar and there are complex rules for canoni-
calization. In practice most authors use a variety of
shortcuts. This means that most compounds are reported
with a variety of near synonyms (thus "2-hydroxy-tolu-
ene", "2-methyl-phenol" are semi-systematic variants for
"1-hydroxy-2-methyl-benzene"). Free-text searching on
chemical names has almost always low precision and
often low recall. It is a common error to assume that deter-
ministic grammars can parse any chemical name; in prac-
tice typographical errors, elisions and trivial fragments
lower precision considerably. Some commercial tools are
available but their algorithms are closed and little research
has been done on their precision and recall. We suspect
that they are composed of lexicons and heuristics but have
no information on how they are maintained, especially in
light of revisions of naming conventions.
Issues with chemical names
Chemical names can be used with more or less specificity.
Thus "1,4-dichlorobenzene" is unambiguous in any con-
text. However there are several areas where more generic
language is used. This can arise because:
• The name refers to a class of compounds, whose mem-
bers have similar structures and/or properties: "steroids",
"amino acids", "monosaccharides", "polychlorinated
biphenyls".
• The substance is a mixture of compounds: "60–80 pet-
rol", "xylenes", "the phospho-inositols"
• The substance has not been fully identified: "the estra-
diol monobenzoate was ..." (there are two possibilities)
• The stereochemistry is ambiguous. The possibilities (in
decreasing order of merit) include:
Stereochemistry is known and reported.
Table 1: Isomers of Glutamic Acid
Name(s)
611 glutamic acid
33032 L-glutamic acid
23327 D-glutamic acidBMC Bioinformatics 2005, 6:180 http://www.biomedcentral.com/1471-2105/6/180
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Stereochemistry is unknown and reported as such.
Stereochemistry is partially known and reported as such.
Stereochemistry is not reported but is unknown
Stereochemistry is not reported but is known
Stereochemistry is partially reported but is completely known
Stereochemistry is reported and is wrong
"Glutamic acid" is an example of ambiguity through
unspecified stereochemistry. Thus PubChem lists the
three isomers (Table 1).
A structure without any stereo information is more valua-
ble than one with partial information of unknown qual-
ity. The InChI [9] is an extremely powerful tool here. We
have recently shown that "staurosporine" reported in
publications and suppliers catalogs contains many
instances of incorrect stereochemistry, and some partially
correct and incorrect. Given that this is a single substance,
its structure and absolute configuration has been known
for a considerable time there is no reason for using any
structure other than PubChem CID: 44259
• Ionization
Protons are labile in aqueous systems and (for example)
aminoacids can have several ionization states. The impor-
tance of ionization details varies;
"Acetic acid (0.1 M) was added..." [ionization state
irrelevant]
Acetic acid forms a hydrogen-bonded dimer in the crystal. [sin-
gle species, determinable by crystallography]
We computed the structure of glycine zwitterion acid
(NH3
+CH2CO2
-) in the gas-phase [single species, distinct from
NH2CH2CO2H]
"Glutamic acid is the most common excitatory neurotransmit-
ter in the CNS" [irrelevant in macroscopic experiment, critical
in modelling action at receptor]
• Tautomerism
Many neutral compounds, particularly with heteroatoms
have mobile hydrogens in solution. Thus 2-hy-droxy pyri-
dine (see Figure 1) exists as both forms with very rapid
interchange. PubChem (as with many other systems) lists
them as the same compound (CID8871) and gives the
many synonyms including "2(1H)-Pyridinone" and "2-
HYDROXY-PYRIDINE". InChI[9] has an extensive system
for detecting tautomerism in compounds with heter-
oatoms, but does not yet address carbon compounds (e.g.
CH2=CHOH as a tautomer of ethanal (acetaldehyde,
CH3-CH=O).
• Imprecise or polysystemic use
This often occurs when a chemical entity is incorporated
into a larger system
"This polysaccharide has a high mannose content" means "...
contains many mannosyl fragments ..."
"HIV protease has a catalytic aspartic acid..." means "... an
aspartyl residue ..."
The preceeding discussion shows how ambiguity and loss
of information can occur if structured procedures are not
followed. The examples in Table 2 show some suggested
approaches to markup which can re-capture much of the
information loss described above. The last example refer-
ences a generic name, monosaccharide, in the IUPAC
guide[2] to organic nomenclature with a suggested use of
identifiers.
Case studies
In this second section, we take 3 articles from BMC publi-
cations and show the success and problems of extracting
chemistry in machine-understandable form. These have
been randomly selected and do not necessarily reflect the
average quality of BMC publications. We note that in our
other studies of chemical text very few publications were
error-free.
Case study 1: Identification of compounds in discourse and 
reagents in methods[13]
The abstract is typical of the discourse:
Tautomers of Hydroxypyridine Figure 1
Tautomers of HydroxypyridineBMC Bioinformatics 2005, 6:180 http://www.biomedcentral.com/1471-2105/6/180
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Background
Recent studies indicate that the G protein-coupled receptor
(GPCR) signaling machinery can serve as a direct target of
reactive oxygen species, including nitric oxide (NO) and S-
nitrosothiols (RSNOs). To gain a broader view into the way
that receptor-dependent G protein activation – an early step in
signal transduction – might be affected by RSNOs, we have
studied several receptors coupling to the Gi family of G proteins
in their native cellular environment using the powerful func-
tional approach of [35S]GTPgammaS autoradiography with
brain cryostat sections in combination with classical G protein
activation assays.
Results
We demonstrate that RSNOs, like S-nitrosoglutathione
(GSNO) and S-nitrosocysteine (CysNO), can modulate GPCR
signaling via reversible, thiol-sensitive mechanisms probably
involving S-nitrosylation. RSNOs are capable of very targeted
regulation, as they potentiate the signaling of some receptors
(exemplified by the M2/M4 muscarinic cholinergic receptors),
inhibit others (P2Y12 purinergic, LPA1lysophosphatidic acid,
and cannabinoid CB1 receptors), but may only marginally
affect signaling of others, such as adenosine A1, µ-opioid, and
opiate related receptors. Amplification of M2/M4 muscarinic
responses is explained by an accelerated rate of guanine nucle-
otide exchange, as well as an increased number of high-affinity
[35S]GTP?S binding sites available for the agonist-activated
receptor. GSNO amplified human M4 receptor signaling also
under heterologous expression in CHO cells, but the effect
diminished with increasing constitutive receptor activity.
RSNOs markedly inhibited P2Y12 receptor signaling in native
tissues (rat brain and human platelets), but failed to affect
human P2Y12 receptor signaling under heterologous expression
in CHO cells, indicating that the native cellular signaling part-
ners, rather than the P2Y12 receptor protein, act as a molecular
target for this action.
Conclusion
These in vitro studies show for the first time in a broader gen-
eral context that RSNOs are capable of modulating GPCR sig-
naling in a reversible and highly receptor-specific manner.
Given that the enzymatic machinery responsible for endogenous
NO production is located in close proximity with the GPCR sig-
naling complex, especially with that for several receptors whose
signaling is shown here to be modulated by exogenous RSNOs,
our data suggest that GPCR signaling in vivo is likely to be sub-
ject to substantial, and highly receptor-specific modulation by
NO-derived RSNOs.
The above contains reference to a considerable numbers
of individual compounds. The authors helpfully publish
a table of abbreviations to assist in the compound identi-
fication process (Figure 2). Using this as our data, we have
attempted to identify (Table 3) the "small-molecules"
mentioned in the discourse. Using PubChem and occa-
sional suppliers catalogs, the elapsed real time was about
1 hour. It can be seen that of 19 molecules, 15 were iden-
tified without problems or error, 2 were not (CysNOGly
and Glu-CysNO) and 2 required additional expertise by
the reader. We estimate that it would take an author the
same amount of time to add PubChem IDs for novel com-
pounds and much less time if they were in common use
in their laboratory.
It is only a little additional effort to convert each molecule
to a more formal description expressed in e.g. CML[5] and
which can carry not only an atom connection table and
the corresponding InChI identifer, but also molecule
"meta-data" describing the provenance of the
information:
<cml:molecule xmlns:cml="http://www.xml-cml.org/
schema/cml2/core" title="carbacholine">
Table 2: Examples of approaches to chemical Identification.
Prose description More precise suggested naming using the CML[5] approach Type of information
Acetaldehyde has a general narcotic action <p><cml:molecule> <cml:identifier convention="iupac:inchi">1/C2H4O/
c1-2-3/h2H,1H3</cml:identifier> <cml:identifier 
convention="pubchem:CID">177</cml:identifier> </cml:molecule> has a 
...</p>
precise, redundant
Benzo(a)pyrene is a potent mutagen and 
carcinogen
<p><cml:molecule><cml:identifier convention="pubchem:CID">2336</cm 
l:identifier></cml:molecule> is a ...</p>
precise
glycine (1 mmol) was added ... <p><cml:molecule title="glycine"><cml:identifier 
convention="iupac:inchi">1/C2H5NO 2/c3-1-2(4)5/h1,3H2,(H,4,5)</cml: 
identifier></cml:molecule> is a ...</p>
hydrogens mobile
calculations on glycine zwitterion... <p><cml:molecule title="g><cml:identifier 
convention="pubchem:CID">InChI=1/C2H5NO2/c3-1-2(4)5/h1H3,3H2</
cml: identifier></cml:molecule> is a ...</p>
hydrogens precise
... a monosaccharide transporter... <p>a <cml:molecule title="monosaccharide"><cml:ident ifier 
convention="iupac:carbohydrate">2 -Carb-2</cml:identifier></cml:mol 
ecule> transporter ...</p>
DataBMC Bioinformatics 2005, 6:180 http://www.biomedcentral.com/1471-2105/6/180
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<cml:metadataList title="generated automatically from
Openbabel">
<cml:metadata name="dc:creator" content="OpenBabel
version 1-100.1"/>
<cml:metadata name="dc:description" content="Conver-
sion of legacy filetype to CML"/>
<cml:metadata name="dc:identifier" content="InChI"/>
<cml:metadata name="dc:content"/>
<cml:metadata name="dc:rights" content="open"/>
<cml:metadata name="dc:type" content="chemistry"/>
<cml:metadata name="dc:contributor" content="rzepa"/
>
<cml:metadata name="dc:creator" content="Openbabel
V1-100.1"/>
<cml:metadata name="dc:date" content="Tue May 17
12:02:50 BST 2005"/>
<cml:metadata name="cmlm:structure" content="yes"/>
</cml:metadataList>
<cml:identifier convention="iupac:inchi">InChI=1/
C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-
3H3,(H-,7,9);1H</cml:identifier>
<cml:atomArray atomID="a1 a2 a3 a4 a5 a6 a7 a8 a9 a10
a11 a12 a13"
 elementType="N C C O C O N C C C H H Cl"
 formalCharge="1 0 0 0 0 0 0 0 0 0 0 0 -1"
 x2="-1.892900 -1.178500 -0.464000 0.250500
0.964900 0.964900 1.761800
-2.305400 -2.476300 -1.480400 2.174300 2.476300 -
1.921800"
 y2="0.415300 0.827800 0.415300 0.827800 0.415300
-0.409700 0.628800 1.129800
-0.168000 -0.299200 1.343300 0.216300 -1.343300"/>
<cml:bondArray atomRef1="a1 a1 a1 a1 a2 a3 a4 a5 a5 a7
a7"
 atomRef2="a2 a8 a9 a10 a3 a4 a5 a6 a7 a11 a12"
 order="1 1 1 1 1 1 1 2 1 1 1"/>
</cml:molecule>
Such molecular datuments can be embedded in any XML-
based document in a manner which can if needed survive
e.g. journal production processes, and where the molecu-
lar information can be extracted and re-used at any stage.
Case study 2: Identity and properties of synthesised 
compounds[14]
Our critique of the chemistry requires context, given by
the abstract:
Abstract background
Kynureninase is a key enzyme on the kynurenine pathway of
tryptophan metabolism. One of the end products of the pathway
is the neurotoxin quinolinic acid which appears to be responsi-
ble for neuronal cell death in a number of important neurolog-
ical diseases. This makes kynureninase a possible therapeutic
target for diseases such as Huntington's, Alzheimer's and AIDS
related dementia, and the development of potent inhibitors an
important research aim.
Abbreviations used in reference 13 Figure 2
Abbreviations used in reference 13.BMC Bioinformatics 2005, 6:180 http://www.biomedcentral.com/1471-2105/6/180
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Results
Two new kynurenine analogues, 3-hydroxydesaminokynure-
nine and 3- methoxydesami-nokynurenine, were synthesised as
inhibitors of kynureninase and tested on the tryptophan-
induced bacterial enzyme from Pseudomonas fluorescens, the
recombinant human enzyme and the rat hepatic enzyme. They
were found to be mixed inhibitors of all three enzymes display-
ing both competitive and non competitive inhibition. The 3-
hydroxy derivative gave low Ki values of 5, 40 and 100 nM
respectively. [...]
Conclusion
For kynureninase from all three species the 2-amino group was
found to be crucial for activity whilst the 3-hydroxyl group
played a fundamental role in binding at the active site
presumably via hydrogen bonding. The potency of the various
inhibitors was found to be species specific. The 3-hydroxylated
inhibitor had a greater affinity for the human enzyme, consist-
ent with its specificity for 3-hydroxykynurenine as substrate,
whilst the methoxylated version yielded no significant differ-
ence between bacterial and human kynureninase. [...]
We note that "quinolinic acid" has four mentions in the
text, but its formula is not given. We took roughly three
minutes to identify CID1066 in PubChem, with the addi-
tional useful information (from Medline/MeSH):
A metabolite of tryptophan with a possible role in neurodegen-
erative disorders. Elevated CSF levels of quinolinic acid are cor-
related with the severity of neuropsychological deficits in
patients who have AIDS
The name "3-hydroxydesaminokynurenine" [the synthe-
sized compound (4) presents a more serious problem.
Although the structure is given in a diagram, the stereo-
genic centre is not marked. It would be a reasonable
assumption that "kynurenine" refers to a natural product
which is only found in one enantiomeric form and "desa-
mino" was also chiral. Careful reading (requiring chemi-
cal expertise) showed that the authors had probably
synthesised a racemic mixture, since they started with
achiral compounds and did not report chiral reagents or a
resolution step. The compound should have been
reported as (R/S)-3-hydroxydesaminokynurenine or
(much better) as the IUPAC-like name "IUPAC Name: (R/
S) 2-amino-4-(3-hy-droxy-phenyl)-4-oxo-butanoic acid".
Indeed many referees and editors would have insisted on
Table 3: Identification of Small-molecules noted in Ref. 14
abbreviation author name PubChem ID Notes
Not found directly in PubChem. Located in 
supplier's catalog. Synonym from that found in 
PubChem
2MeSADP 2-methylthio-ADP [121990]
5-HT 5-hydroxytryptamine 5202
CCh carbacholine 521353
CP-55940 (-)-3-[2-hydroxy-4-(1,1-dimeth ylheptyl)-phenyl]-
4-[3-hydroxyp ropyl]cyclohexan-1-ol
104895 IUPAC: 5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-
hydroxyprop yl)cyclohexyl]-phenol
CysNO S-nitrosocysteine 39933
CysNOGly S-nitroso-cysteinyl-glycine Text search on PubChem found wrong compound. 
Not found in major supplier
DAMGO [D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin 104742
DPCPX 8-cyclopentyl-1,3-dipropylxanthi ne 1320
Glu-CysNO L-?-glutamyl-S-nitrosocysteine Identity unresolved
GSH glutathione 745
GSNO S-nitrosoglutathione 104858
LPA lysophosphatidic acid 3987
NA noradrenaline 951 PubChem CID covers both racemic and d-
enantiomer
NO nitric oxide 84878 PubChem also lists 945 (with incorrect formula 
HNO) as nitric oxide
NOBF4 nitrosodium tetrafluoroborate 151929 Paper has a typographical error for "nitrosonium". 
Structure in PubChem is wrong (formula should 
be NO+BF4
-, not H2NO+.BF4
-)
SNAP S-nitroso-N-acetyl-D,L-penicill amine 5231 PubChem does not list stereochemistry
RSNO S-nitrosothiol Appears to be a generic compound (R-S-N=O)
SNP sodium nitroprusside 26256BMC Bioinformatics 2005, 6:180 http://www.biomedcentral.com/1471-2105/6/180
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this specification. In the event, as we show below, this is
not the reported compound!
The tools we are proposing would immediately have que-
ried both these concerns at time of authoring and, had
they been available to the technical editor would have
produced a more useful and more easily readable paper.
The publication of the synthesis or re-synthesis of com-
pounds must be accompanied by analytical and property
data to prove purity and identitity. The ritualistic presen-
tation shown below (Figure 3) as copied from the manu-
script is entirely typical of most chemical publications.
Note that it is visually challenging to read and this is
entirely due to the publisher's requirements of using a sys-
tem designed to save paper rather than communicate use-
ful information.
For each compound this compressed information is
(manually) created from some or all of:
1. An elemental analysis (probably in machine-under-
standable form)
2. A calculated composition for the compound (machine
understandable)
3. An infrared spectrum (machine understandable)
4. A 1H NMR spectrum (machine understandable)
5. A 13C NMR spectrum (machine understandable)
6. A low resolution mass spectrum (machine
understandable)
7. A high resolution mass spectrum (machine
understandable)
For the publication, the authors have to measure peak
heights from the spectrum (possibly with a ruler), and
transcribe them to a Word or PDF format, probably by
typing the values or cut-n-pasting them. We have
developed an Open Source robot (OSCAR)[8] which can
understand this data if it is syntactically correct, and the
result is shown in Figure 4:
The coloured parts are those that adhere to the publica-
tion guidelines. We found 7 changes that had to be made
to the punctuation (missing punctuation, syntactic varia-
tion is common in many chemical papers). OSCAR can
then understand and check the data. For compound [4]
OSCAR produces the errror message:
There are fewer H atoms by NMR integration (7) than
there are by elemental analysis (12)
This is acceptable because there are exchangeable groups.
However OSCAR also gives the error flag:
There are more C-NMR environments (11) than there are
C atoms from elemental analysis (10).
A linear text-based description of experimental detail and  data taken from Ref. 14 Figure 3
A linear text-based description of experimental detail and 
data taken from Ref. 14.BMC Bioinformatics 2005, 6:180 http://www.biomedcentral.com/1471-2105/6/180
Page 10 of 15
(page number not for citation purposes)
as it found the string "114.47 120.78". We also do not
understand this and it may be an error (or it could be a
solvent peak or other impurity). OSCAR also had prob-
lems interpreting the chemical formula: "C11H14NO4"
which in fact turns out to be a charged species. In fact the
compounds are poorly identified. They appear to be not
the aminoacids "3-Hydroxydesami-nokynurenine (4)"
and "3-Methoxydesaminokynurenine (5)" but their
hydrochloride salts. This is not a trivial error; the melting
points and infrared spectra of the parents and their salts
will be significantly different and would cause errors if
transcribed unthinkingly from the paper.
Even with OSCAR it took one of us ca 45 minutes to make
sure that the above analysis was correct. From several
anecdotal conversations with typical authors we estimate
that it took about 2 hours to prepare this part of the sub-
mission; a thorough reviewer might take 0.5 hour to deci-
pher it. All of this is unnecessary if the original connection
tables, spectra and analytical data were made available in
uncorrupted form. As it is, much of the original data is
lost; using the reported peaks OSCAR does its best to rec-
reate what the spectrum might have looked like (Figure
5). Precise peak shapes and traces of impurities are lost in
this representation.
Case study 3. Identity of compounds and preservation of 
calculations[15]
Here too a number of small-molecules are reported with-
out formulae;
Background [...] Phenols and anilines are generally recognized
as substrates of the heme peroxidases (donor: H2O2 oxidore-
ductases EC 1.11.17). The peroxidases catalyze oxidation of
the substrates by hydrogen peroxide or alkyl peroxides, usually
but not always, via free-radical intermediates [1,2]. Nonphe-
nolic compounds, such as indole-3-acetic acid, phenylenedi-
amines, ferrocenes, phenothiaz-ines, phenoxazines, have also
been investigated as peroxidase substrates [2-5]. Steady-state
kinetics of peroxidase action has been described as a ping-pong
scheme with compound I and compound II formation [1].
This paper also has issues with the identity of compounds
(Figure 6). This is again a visually unacceptable format
dictated by the prevailing business model of chemical
publishing. Note "Napthyl" is misspelt, presumably
because it has been (mis)typed by the authors, which
would give unnecessary problems to chemical text-mining
robots. Worse, the identity of AHA5 is genuinely unclear,
in that the connection could be to either of the phenyl
groups in the fragment: "Ph-C(O)N(-OH)-Ph". BHA (also
described elsewhere by "benzhydroxamic acid") has no
structural or compositional formula. Worse, BHA in the
PDB ligand collection refers to 2-hydroxy-4-amino-ben-
zoic acid (a completely different compound); "benzhy-
droxamic acid" has code BHO.
Another section of this article describes various computa-
tional modelling techniques applied to these molecules;
here we can assume that the authors had precise coordi-
nates for all the computed species available at the end of
the research, although none of this data is actually made
available via the final published article. Some of this data
OSCAR output from the text-based description in Ref 14 Figure 4
OSCAR output from the text-based description in Ref 14.BMC Bioinformatics 2005, 6:180 http://www.biomedcentral.com/1471-2105/6/180
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is used to drive a docking program, which itself implies a
protocol used to specify various run-time parameters.
Some of these are declared in the article, many probably
default to values set internally within the program. There
are also ambiguities in the declared computational
protocol:
The optimized geometry of molecules was used for energies and
charges calculations with a 6-31G basis set using RHF and
B3PW91 (Density Functional Theory).
Here, the RHF and the B3PW91 protocols are mutually
exclusive; either one or the other could have been used,
but not in combination. Mapping either protocol to e.g.
the appropriate input for the program package used can
OSCAR generated spectrum of analytical information reported in Ref 14 Figure 5
OSCAR generated spectrum of analytical information reported in Ref 14.
Structure diagram reported in Ref 15 Figure 6
Structure diagram reported in Ref 15.BMC Bioinformatics 2005, 6:180 http://www.biomedcentral.com/1471-2105/6/180
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also be a challenge for anyone not totally familiar with the
program; program manuals are still designed largely for
human rather than machine use. Such ambiguities, and
lack of data, make repetition of the modelling more diffi-
cult for others.
A proposed infrastructure
It should now be clear that the current system of commu-
nicating chemistry (which is common to all publishers
and all disciplines) is inefficient, costly, lossy, and of
questionable quality. We present a new XML-based
approach which we show:
• takes less time
• conveys more information
• is easier to read
• allows published data to be aggregated and re-used
We note that when starting to draft a publication the
author already has
• free text (A) (probably in handwritten form)
• properties (B) (probably handwritten form)
• spectra (C) (probably in digital form)
• molecules (D) (probably in MOL or ChemDraw files)
Electronic lab notebook technology is not well advanced
in chemistry; our architecture would provide a good
method for preserving conventional data. It looks as
shown in Figure 7 (blue = XML):
The author would then use a tool which can manage struc-
tured XML documents and provide normal textual sup-
port (spellchecks, etc.). There are 4 additional tools
required to support chemical information:
• A. Chemical lexical tool(AA) which can (a) parse free
text(A) for possible compound names (b) look them up
or (c) parse them to create connection table and (d) insert
a reference (AX) to the lexicon in the text, e.g.:
... When foobarone is broken down, the presence of indole can
be detected ...
might be marked up as
Data-flow illustrating the use of XML Figure 7
Data-flow illustrating the use of XML.BMC Bioinformatics 2005, 6:180 http://www.biomedcentral.com/1471-2105/6/180
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... When <cml:molecule name="foobarone" dictRef="nat-
prod:foobarone"/> is broken down, the presence of
<cml:molecule>
<identifier convention="iupac:inchi" title="indole">1/
C8H7N/c1-2-4-8-7(3-1)5-6-9-8/h1-6H,9H</identifier>
</cml:molecule>
indole can be detected ...
• B. A controlled vocabulary (BB) of property types is used
in a template to capture properties (B) and create a CML
table (BX), e.g.
yield(93%), M.Pt. 273-275°C
becomes
<cml:list>
 <cml:property dictRef="cml:yield">
 <cml:scalar units="cml:percent">93%lt;/cml:scalar>
 </cml:property>
 <cml:property dictRef="cml:mpt">
 <cml:scalar units="cml:celsius" minValue="273"
maxvalue="275"/>
 </cml:property>
</cml:list>
• C. Spectra in legacy format (C) are automatically con-
verted to CMLSpect or AniML (CX).
• D. Molecules created in a conventional editor are either
emitted in CML (DX) or automatically converted from
legacy (D) .
The result is a single structured XML "datument"[16] con-
taining fine-grained markup of facts (molecules, measure-
ments, properties, chemical names). This datument can
be used to create derivatives such as the "full-text" or the
"supplemental data". The complete datument (if Open)
or the "data" if not is then reposited (XX) where it can be
harvested. New compounds with their names are fed back
into the lexicon and all compound/property data is avail-
able for datamining and computational re-use (e.g. for
further in silico prediction. A human or robot reader has
access to the same lexicons and dictionaries as the author
so that the semantics and ontology of authoring are the
same as those of reading (and of preservation).
Metadata and rights
The social aspects of metadata and rights were addressed
in (1). To meet these we place special emphasis on the
XML and its metadata. Fine-grained XML (e.g. <sca-
lar>...</scalar> or <molecule>...</molecule> represents
facts which can be identified as Open and not the property
of the publisher. Hyperlinks and structure for semantics
(e.g. identification of compounds in PubChem) are also
Open. Tools such as XSLT can then extract the factual,
non-copyrightable information with little technical prob-
lem. Rights should be explicitly marked up. If the pub-
lisher supports Open Access [17] and also Open Data then
it is valuable to label the appropriate components with
Open licenses, such as the RDF metadata provided by Cre-
ative Commons. It is also possible to preserve authors'
moral rights and provenance of data re-used within the
paper (e.g. spectra of molecules or coordinates of protein
structures).
Realising the vision
The transition to this architecture will have a cost, so short
term-benefits are particularly attractive. Moreover most of
the parties are not used to a communal approach (pres-
sures are normally per-institution and per-publisher).
Costs
• Time lost in understanding and changing to a new
system.
• New tools might cost money, or have to come from non-
centralised budgets
• Only supported by a subset of publishers
• Communal deposition of data goes against the secretive
culture
• Publishers have to invest in new system and react to
community expectations
Benefits
• Open Access and Open Data[16]
• Greater quality in publications
• Data in theses and papers can be interchanged
• Greater readability, usability and innovation in
publications
• Repository provides complete data record for labora-
tory, institution and worldBMC Bioinformatics 2005, 6:180 http://www.biomedcentral.com/1471-2105/6/180
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• Modern informatics tools allow new types of search and
aggregation
• Considerable time-savings during publication
• More efficient publishing reduces author frustration and
time to publication
• and most importantly the arrival of the Scientific
Semantic Web, allowing robots to read and take action on
publications.
The benefits should also be clear for most individuals and
organisations:
• funders can ensure a much higher of dissemination of
funded data will be available
• institutions mandate a greater proportion of funded sci-
ence published; better visibility and preservation
• researchers spend less time on unproductive operations
• reviewers have easier access to background ontology of
data in documents
• editors get greater automation
• publishers are relieved of need to archive supplemental
data
• readers have information prosthetics for easier and
faster reading
• librarians develop one of the best early repository appli-
cations in the digital age
Potential
Because the chemical information is structured we now
have a biocheminformatics cycle (this term – with spell-
ing as here -is in modest use. We suggest its adoption to
describe the management of chemical information in
biosciences and not just in biochemistry) where, for the
first time, large scale robotic data analysis can take place
(Figure 8).
The data in the research (laboratory, in silico, or both) are
published in a lossless manner. Molecules and their prop-
erties have unique identifiers as described above and can
be integrated into mainstream bioinformatics in the same
manner as collections such as PubChem, MSDChem (at
EBI), KEGG, etc. They will bring the added value of con-
sistently captured property data and spectra. We also
expect that many in silico properties will then be system-
atically added.
Compliance and adoption
The current dissemination of data through publishers is
largely unsatisfactory. Some publishers, such as the Inter-
national Union of Crystallography, see it as core business
and others in the biosciences agree to link to international
databanks. Many publishers allow the deposition of fac-
tual "supplementary data" but our experience with main-
stream chemical publishers is that it is an unwelcome
chore, poorly resourced and maintained, and with virtu-
ally no quality control or curation over the content. We
believe that many publishers would welcome a model
where they were no longer involved in data repositing.
The introduction of structured authoring tools will help
this process considerably. Templates can be created for the
chemical components described above and where the
information exists in XML (connection tables, spectra,
properties) it should be as easy as for committed authors
as using a semantically void tool (e.g. Word). Where infor-
mation needs to be converted from legacy formats we
have created Open Web Services which publishers (and
authors) may clone and customise. The main technical
challenge will be the management of chemical names in
free text.
Conclusions and the future
The analysis presented here introduces the basic concepts
of chemistry in bioinformatics. Many areas remain to be
addressed; we briefly describe two below which have
immediate application.
A Biocheminformatics Cycle Figure 8
A Biocheminformatics Cycle.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Bioinformatics 2005, 6:180 http://www.biomedcentral.com/1471-2105/6/180
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Reactions
Chemical reactions are very patchily abstracted from the
literature and the products are almost always closed. The
motivation for the primary publication of reactions in
bioscience includes:
1. record of synthesis of compound and proof thereof
2. record of an experimental protocol (e.g. biotinylation)
3. record of a biochemical reaction, including xenobiotic
processes
4. description of systems biochemistry (coupled reaction
pathways)
5. understanding of an enzyme mechanism
CMLReact (an extension of CML) has been created[18] to
support these catagories of reaction. Items 1-2 require
identical support as in mainstream chemistry (e.g. in jour-
nals supporting organic synthesis). Item 3 can be sup-
ported by CMLReact though there is little current
experience. Item 4 is supported by SBML[19] and efforts
such as BioPAX[20] (in which CML is a tool). Item 5 is
particularly exciting and exemplified by our MACiE data-
base where 150+ enzymes with 3D structures and pro-
posed mechanisms have been collected[21]. Currently the
abstraction is manual and expensive, but if the ideas in the
current paper are implemented we shall present an exten-
sion whereby mechanisms can be relatively cheaply
captured at source. This would be a major new resource in
bioinformatics.
Evaluation metrics
The primary motivation for a publication, of course, is cit-
ability and the technology we describe raises the fear
among chemists that the data in it might actually be read,
analysed and re-used. However it also raises the vision of
changing the "citation economy" (which values market
perception) to a "reuse economy" where the data in an
article (or as we prefer, a "datument") are valued by how
often they are re-used.
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